JATT III Acquisition Corp Ordinary Shares

JATT III Acquisition Corp Ordinary Shares(JTTT)股票分析

$10.300

0.000 (0.00%)收盘时

Loading chart…
最高
10.320
开盘
10.250
成交量加权均价
10.28
成交量
5.85K
市值
—
最低
10.213
成交额
60.10K
企业价值/息税折旧摊销前利润(TTM)
0.00

JATT III Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any business combination target, and the Company has not initiated any substantive discussions, directly or indirectly, with any business combination target. The Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. The Company is not engaged in any business operations and has not generated any revenue.

AI 分析 of JATT III Acquisition Corp Ordinary Shares (JTTT)

持有

JTTT is not a strong buy right now due to its low RSI of 37.401, indicating potential oversold conditions, and a current price of 10.30, which is close to its 52-week low of 10.00. The stock has shown a 20-day change of -4.63%, suggesting a downward trend. However, the projected final change of +1047.66% based on historical patterns indicates potential for significant upside in the long term. The main risk is its current ratio of 0.28, indicating liquidity concerns.

估值指标

JATT III Acquisition Corp Ordinary Shares(JTTT)当前预期市盈率为 0.00,5 年平均预期市盈率为 。

预期市盈率

5 年均值 P/E
当前P/E
0.00

预期 EV/EBITDA

5 年均值 EV/EBITDA
当前EV/EBITDA
0.00

预期市销率

5 年均值 P/S
当前P/S
0.00

事件时间线

2026-09-21 (ET)

16:00:00

Nscale Limited Files for IPO, Plans to List on NYSE

JTTT 常见问题 —— 由 Alphio AI 解答

JATT III Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any business combination target, and the Company has not initiated any substantive discussions, directly or indirectly, with any business combination target. The Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. The Company is not engaged in any business operations and has not generated any revenue.

JTTT is not a strong buy right now due to its low RSI of 37.401, indicating potential oversold conditions, and a current price of 10.30, which is close to its 52-week low of 10.00. The stock has shown a 20-day change of -4.63%, suggesting a downward trend. However, the projected final change of +1047.66% based on historical patterns indicates potential for significant upside in the long term. The main risk is its current ratio of 0.28, indicating liquidity concerns.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易